GSK (GSK) vs Sanofi (SNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GSK (GSK) has outperformed Sanofi (SNY) over the past year, gaining 7.4% versus a loss of 17.6%. Over five years, GSK leads with a +19.3% price change compared with -17.6% for SNY. Sanofi is the larger company by market cap ($96.17 billion vs $93.46 billion), about 1.0 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 9.4x for GSK). Sanofi offers the higher dividend yield (10.27% vs 1.46%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GSK | SNY |
|---|---|---|
| Share price | $46.65 | $40.14 |
| Market cap | $93.46B | $96.17B |
| 1-day change | +0.24% | -0.24% |
| YTD return | -5.10% | -16.98% |
| 1-year return | +7.36% | -17.56% |
| 5-year return | +19.30% | -17.65% |
| P/E ratio (TTM) | 14.72 | 21.12 |
| Forward P/E | 9.44 | 7.43 |
| EPS (TTM) | $3.17 | $1.90 |
| Dividend yield | 1.46% | 10.27% |
| Annual dividend | $0.68 | $4.12 |
| 52-week high | $61.70 | $52.68 |
| 52-week low | $42.85 | $39.18 |
| Distance from 52-week high | -24.39% | -23.81% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +27.18% | +33.57% |
| Average volume | 3.85M | 2.87M |
| Shares outstanding | 2.00B | 2.40B |
| Employees | 66,841 | 74,846 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GSK has outperformed SNY by 24.9 percentage points over the past year.
- Sanofi trades at a higher earnings multiple (21.1x vs 14.7x trailing P/E).
- Sanofi offers a meaningfully higher dividend yield (10.27% vs 1.46%).
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
GSK vs SNY FAQ
Which is bigger, GSK or Sanofi?
Sanofi (SNY) is larger, with a market capitalization of $96.17B compared with $93.46B for GSK (GSK).
Which stock has performed better over the past year, GSK or SNY?
GSK returned +7.36% over the past 12 months, compared with -17.56% for SNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GSK or SNY?
GSK has the lower trailing P/E at 14.7, versus 21.1 for SNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, GSK or Sanofi?
Sanofi has the higher yield at 10.27%, compared with 1.46% for GSK.
Are GSK and Sanofi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.